Bladder preservation: translating discovery for clinical impact in urothelial cancer
AffiliationDepartment of Radiation Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
MetadataShow full item record
AbstractMuscle-invasive bladder cancer can be treated with either radical cystectomy or bladder preservation approaches, and there is a need for reliable biomarkers to guide the optimal choice of therapy. The recent elucidation of the genomic landscape and biological drivers of bladder cancer has enabled the identification of tumor molecular features that may be helpful in driving clinical decision-making. Here, we summarize recent efforts to develop molecular biomarkers that could be leveraged to guide therapeutic decisions, post-treatment monitoring, and the optimal use of bladder preservation approaches for the effective treatment of muscle-invasive bladder cancer.
CitationMiyamoto DT, Abbosh PH, West CML, Mouw KW. Bladder preservation: Translating discovery for clinical impact in urothelial cancer. Urol Oncol. 2020.
- Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
- Authors: Johnson SB, Yu JB
- Issue date: 2018 Jun 30
- Trimodality bladder preservation therapy for muscle-invasive bladder cancer.
- Authors: Chen RC, Shipley WU, Efstathiou JA, Zietman AL
- Issue date: 2013 Aug
- Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy.
- Authors: Balar A, Bajorin DF, Milowsky MI
- Issue date: 2011 Jun
- Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
- Authors: Efstathiou JA, Mouw KW, Gibb EA, Liu Y, Wu CL, Drumm MR, da Costa JB, du Plessis M, Wang NQ, Davicioni E, Feng FY, Seiler R, Black PC, Shipley WU, Miyamoto DT
- Issue date: 2019 Jul
- Bladder preservation protocols in the treatment of muscle-invasive bladder cancer.
- Authors: Torres-Roca JF
- Issue date: 2004 Nov-Dec